Osteoprotegerin induces morphological and functional alterations in mouse pancreatic islets

Molecular and Cellular Endocrinology

Volumn 331, Issue 1, 2011, Pages 136-142

  Toffoli, Barbara ^a,d   Bernardi, Stella ^b   Candido, Riccardo ^c   Sabato, Nicoletta ^b   Carretta, Renzo ^b   Corallini, Federica ^a   Secchiero, Paola ^a   Zauli, Giorgio ^d   Fabris, Bruno ^b  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF TRIESTE   (Italy)

^c Diabetic Center   (Italy)

^d INSTITUTE FOR MATERNAL AND CHILD HEALTH IRCCS BURLO GAROFOLO   (Italy)

Author keywords

Angiotensin converting enzyme inhibitor; Diabetes; Osteoprotegerin; Renin angiotensin system

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; GLUCOSE; INSULIN; MONOCYTE CHEMOTACTIC PROTEIN 1; OSTEOPROTEGERIN; RAMIPRIL; RAS PROTEIN; RECOMBINANT OSTEOPROTEGERIN; RECOMBINANT PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VASCULAR ADHESION PROTEIN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BODY WEIGHT; CELL INFILTRATION; CONTROLLED STUDY; DRUG EFFICACY; FIBROSIS; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HYPERGLYCEMIA; INSULIN RELEASE; INSULINEMIA; MACROPHAGE; MALE; MONOCYTE; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS ISLET DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE;

ANIMALS; APOPTOSIS; BLOOD GLUCOSE; BLOOD PRESSURE; BODY WEIGHT; CELL LINEAGE; CELL MOVEMENT; CHEMOKINE CCL2; CONNECTIVE TISSUE GROWTH FACTOR; FIBROSIS; GENE EXPRESSION REGULATION; HUMANS; INSULIN; ISLETS OF LANGERHANS; MACROPHAGES; MICE; MONOCYTES; ORGAN SIZE; OSTEOPROTEGERIN; PEPTIDYL-DIPEPTIDASE A; RECEPTOR, ANGIOTENSIN, TYPE 1; SYSTOLE; TRANSFORMING GROWTH FACTOR BETA; VASCULAR CELL ADHESION MOLECULE-1;

EID: 78149412247     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2010.08.019     Document Type: Article

References (54)

1. Avignon A., Sultan A., Piot C., Elaerts S., Cristol J.P., Dupuy A.M. Osteoprotegerin is associated with silent coronary artery disease in high-risk but asymptomatic type 2 diabetic patients. Diabetes Care 2005, 28:2176-2180.
2. Boyle W.J., Simonet W.S., Lacey D.L. Osteoclast differentiation and activation. Nature 2003, 423:337-342.
3. Browner W.S., Lui L.Y., Cummings S.R. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J. Clin. Endocrinol. Metab. 2001, 86:631-637.
4. Candido R., Allen T.J., Lassila M., Cao Z., Thallas V., Cooper M.E., Jandeleit-Dahm K.A. Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosis. Circulation 2004, 109:1536-1542.
5. Candido R., Jandeleit-Dahm K.A., Cao Z., Nesteroff S.P., Burns W.C., Twigg S.M., Dilley R.J., Cooper M.E., Allen T.J. Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice. Circulation 2002, 106:246-253.
6. Candido R., Toffoli B., Corallini F., Bernardi S., Zella D., Voltan R., Grill V., Celeghini C., Fabris B. Human full-length osteoprotegerin induces the proliferation of rodent vascular smooth muscle cells both in vitro and in vivo. J. Vasc. Res. 2010, 47:252-261.
7. Carlsson P.O., Berne C., Jansson L. Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats. Diabetologia 1998, 41:127-133.
8. Chen M.C., Proost P., Gysemans C., Mathieu C., Eizirik D.L. Monocyte chemoattractant protein-1 is expressed in pancreatic islets from prediabetic NOD mice and in interleukin-1 beta-exposed human and rat islet cells. Diabetologia 2001, 44:325-332.
9. Chu K.Y., Lau T., Carlsson P.O., Leung P.S. Angiotensin II type 1 receptor blockade improves beta-cell function and glucose tolerance in a mouse model of type 2 diabetes. Diabetes 2006, 55:367-374.
10. Collin-Osdoby P., Rothe L., Anderson F., Nelson M., Maloney W., Osdoby P. Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. J. Biol. Chem. 2001, 276:20659-20672.
11. Cowling R.T., Gurantz D., Peng J., Dillmann W.H., Greenberg B.H. Transcription factor NF-kappa B is necessary for up-regulation of type 1 angiotensin II receptor mRNA in rat cardiac fibroblasts treated with tumor necrosis factor-alpha or interleukin-1 beta. J. Biol. Chem. 2002, 277:5719-5724.
12. di Mola F.F., Friess H., Martignoni M.E., Di Sebastiano P., Zimmermann A., Innocenti P., Graber H., Gold L.I., Korc M., Buchler M.W. Connective tissue growth factor is a regulator for fibrosis in human chronic pancreatitis. Ann. Surg. 1999, 230:63-71.
13. Donath M.Y., Halban P.A. Decreased beta-cell mass in diabetes: significance, mechanisms and therapeutic implications. Diabetologia 2004, 47:581-589.
14. Ehses J.A., Lacraz G., Giroix M.H., Schmidlin F., Coulaud J., Kassis N., Irminger J.C., Kergoat M., Portha B., Homo-Delarche F., Donath M.Y. IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK rat. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:13998-14003.
15. Emery J.G., McDonnell P., Burke M.B., Deen K.C., Lyn S., Silverman C., Dul E., Appelbaum E.R., Eichman C., DiPrinzio R., Dodds R.A., James I.E., Rosenberg M., Lee J.C., Young P.R. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J. Biol. Chem. 1998, 273:14363-14367.
16. Galluzzi F., Stagi S., Salti R., Toni S., Piscitelli E., Simonini G., Falcini F., Chiarelli F. Osteoprotegerin serum levels in children with type 1 diabetes: a potential modulating role in bone status. Eur. J. Endocrinol. 2005, 153:879-885.
17. Grauslund J., Rasmussen L.M., Green A., Sjolie A.K. Does osteoprotegerin relate to micro- and macrovascular complications in long-term type 1 diabetes?. Scand. J. Clin. Lab. Invest. 2010, 70:188-193.
18. Gross O., Beirowski B., Koepke M.L., Kuck J., Reiner M., Addicks K., Smyth N., Schulze-Lohoff E., Weber M. Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome. Kidney Int. 2003, 63:438-446.
19. Jono S., Ikari Y., Shioi A., Mori K., Miki T., Hara K., Nishizawa Y. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 2002, 106:1192-1194.
20. Kiechl S., Schett G., Wenning G., Redlich K., Oberhollenzer M., Mayr A., Santer P., Smolen J., Poewe W., Willeit J. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 2004, 109:2175-2180.
21. Knudsen S.T., Foss C.H., Poulsen P.L., Andersen N.H., Mogensen C.E., Rasmussen L.M. Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications. Eur. J. Endocrinol. 2003, 149:39-42.
22. Koka V., Huang X.R., Chung A.C., Wang W., Truong L.D., Lan H.Y. Angiotensin II up-regulates angiotensin I-converting enzyme (ACE), but down-regulates ACE2 via the AT1-ERK/p38 MAP kinase pathway. Am. J. Pathol. 2008, 172:1174-1183.
23. Kuno A., Yamada T., Masuda K., Ogawa K., Sogawa M., Nakamura S., Nakazawa T., Ohara H., Nomura T., Joh T., Shirai T., Itoh M. Angiotensin-converting enzyme inhibitor attenuates pancreatic inflammation and fibrosis in male Wistar Bonn/Kobori rats. Gastroenterology 2003, 124:1010-1019.
24. Lau T., Carlsson P.O., Leung P.S. Evidence for a local angiotensin-generating system and dose-dependent inhibition of glucose-stimulated insulin release by angiotensin II in isolated pancreatic islets. Diabetologia 2004, 47:240-248.
25. Leung P.S., Carlsson P.O. Tissue renin-angiotensin system: its expression, localization, regulation and potential role in the pancreas. J. Mol. Endocrinol. 2001, 26:155-164.
26. Lieb W., Gona P., Larson M.G., Massaro J.M., Lipinska I., Keaney J.F., Rong J., Corey D., Hoffmann U., Fox C.S., Vasan R.S., Benjamin E.J., O'Donnell C.J., Kathiresan S. Biomarkers of the osteoprotegerin pathway. Clinical correlates, subclinical disease, incident cardiovascular disease, and mortality. Arterioscler. Thromb. Vasc. Biol. 2010.
27. Malyankar U.M., Scatena M., Suchland K.L., Yun T.J., Clark E.A., Giachelli C.M. Osteoprotegerin is an alpha vbeta 3-induced, NF-kappa B-dependent survival factor for endothelial cells. J. Biol. Chem. 2000, 275:20959-20962.
28. Mangan S.H., Van Campenhout A., Rush C., Golledge J. Osteoprotegerin upregulates endothelial cell adhesion molecule response to tumor necrosis factor-alpha associated with induction of angiopoietin-2. Cardiovasc. Res. 2007, 76:494-505.
29. Martin M.M., Buckenberger J.A., Jiang J., Malana G.E., Knoell D.L., Feldman D.S., Elton T.S. TGF-beta1 stimulates human AT1 receptor expression in lung fibroblasts by cross talk between the Smad, p38 MAPK, JNK, and PI3K signaling pathways. Am. J. Physiol. Lung Cell. Mol. Physiol. 2007, 293:L790-L799.
30. Moran C.S., Cullen B., Campbell J.H., Golledge J. Interaction between angiotensin II, osteoprotegerin, and peroxisome proliferator-activated receptor-gamma in abdominal aortic aneurysm. J. Vasc. Res. 2009, 46:209-217.
31. Mosheimer B.A., Kaneider N.C., Feistritzer C., Djanani A.M., Sturn D.H., Patsch J.R., Wiedermann C.J. Syndecan-1 is involved in osteoprotegerin-induced chemotaxis in human peripheral blood monocytes. J. Clin. Endocrinol. Metab. 2005, 90:2964-2971.
32. Murphy M., Godson C., Cannon S., Kato S., Mackenzie H.S., Martin F., Brady H.R. Suppression subtractive hybridization identifies high glucose levels as a stimulus for expression of connective tissue growth factor and other genes in human mesangial cells. J. Biol. Chem. 1999, 274:5830-5834.
33. Ou D., Metzger D.L., Wang X., Huang J., Pozzilli P., Tingle A.J. TNF-related apoptosis-inducing ligand death pathway-mediated human beta-cell destruction. Diabetologia 2002, 45:1678-1688.
34. Rasmussen L.M., Tarnow L., Hansen T.K., Parving H.H., Flyvbjerg A. Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic patients. Eur. J. Endocrinol. 2006, 154:75-81.
35. Ruperez M., Ruiz-Ortega M., Esteban V., Lorenzo O., Mezzano S., Plaza J.J., Egido J. Angiotensin II increases connective tissue growth factor in the kidney. Am. J. Pathol. 2003, 163:1937-1947.
36. Satoh M., Kashihara N., Yamasaki Y., Maruyama K., Okamoto K., Maeshima Y., Sugiyama H., Sugaya T., Murakami K., Makino H. Renal interstitial fibrosis is reduced in angiotensin II type 1a receptor-deficient mice. J. Am. Soc. Nephrol. 2001, 12:317-325.
37. Schoppet M., Sattler A.M., Schaefer J.R., Herzum M., Maisch B., Hofbauer L.C. Increased osteoprotegerin serum levels in men with coronary artery disease. J. Clin. Endocrinol. Metab. 2003, 88:1024-1028.
38. Schrader J., Rennekamp W., Niebergall U., Schoppet M., Jahr H., Brendel M.D., Horsch D., Hofbauer L.C. Cytokine-induced osteoprotegerin expression protects pancreatic beta cells through p38 mitogen-activated protein kinase signalling against cell death. Diabetologia 2007, 50:1243-1247.
39. Secchiero P., Corallini F., Pandolfi A., Consoli A., Candido R., Fabris B., Celeghini C., Capitani S., Zauli G. An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction. Am. J. Pathol. 2006, 169:2236-2244.
40. Seccia T.M., Belloni A.S., Kreutz R., Paul M., Nussdorfer G.G., Pessina A.C., Rossi G.P. Cardiac fibrosis occurs early and involves endothelin and AT-1 receptors in hypertension due to endogenous angiotensin II. J. Am. Coll. Cardiol. 2003, 41:666-673.
41. Simonet W.S., Lacey D.L., Dunstan C.R., Kelley M., Chang M.S., Luthy R., Nguyen H.Q., Wooden S., Bennett L., Boone T., Shimamoto G., DeRose M., Elliott R., Colombero A., Tan H.L., Trail G., Sullivan J., Davy E., Bucay N., Renshaw-Gegg L., Hughes T.M., Hill D., Pattison W., Campbell P., Sander S., Van G., Tarpley J., Derby P., Lee R., Boyle W.J. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997, 89:309-319.
42. Theoleyre S., Wittrant Y., Couillaud S., Vusio P., Berreur M., Dunstan C., Blanchard F., Redini F., Heymann D. Cellular activity and signaling induced by osteoprotegerin in osteoclasts: involvement of receptor activator of nuclear factor kappaB ligand and MAPK. Biochim. Biophys. Acta 2004, 1644:1-7.
43. Thomas H.E., McKenzie M.D., Angstetra E., Campbell P.D., Kay T.W. Beta cell apoptosis in diabetes. Apoptosis 2009, 14:1389-1404.
44. Tikellis C., Cooper M.E., Thomas M.C. Role of the renin-angiotensin system in the endocrine pancreas: implications for the development of diabetes. Int. J. Biochem. Cell Biol. 2006, 38:737-751.
45. Tikellis C., Wookey P.J., Candido R., Andrikopoulos S., Thomas M.C., Cooper M.E. Improved islet morphology after blockade of the renin-angiotensin system in the ZDF rat. Diabetes 2004, 53:989-997.
46. Ueland T., Jemtland R., Godang K., Kjekshus J., Hognestad A., Omland T., Squire I.B., Gullestad L., Bollerslev J., Dickstein K., Aukrust P. Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. J. Am. Coll. Cardiol. 2004, 44:1970-1976.
47. Ueland T., Yndestad A., Oie E., Florholmen G., Halvorsen B., Froland S.S., Simonsen S., Christensen G., Gullestad L., Aukrust P. Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure. Circulation 2005, 111:2461-2468.
48. Xiang G.D., Pu J.H., Zhao L.S., Sun H.L., Hou J., Yue L. Association between plasma osteoprotegerin concentrations and urinary albumin excretion in type 2 diabetes. Diabet. Med. 2009, 26:397-403.
49. Yoshiji H., Kuriyama S., Yoshii J., Ikenaka Y., Noguchi R., Nakatani T., Tsujinoue H., Fukui H. Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology 2001, 34:745-750.
50. Yuan L., Li X., Xu G.L., Qi C.J. Effects of renin-angiotensin system blockade on islet function in diabetic rats. J. Endocrinol. Invest. 2010, 33:13-19.
51. Zauli G., Corallini F., Bossi F., Fischetti F., Durigutto P., Celeghini C., Tedesco F., Secchiero P. Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo. Blood 2007, 110:536-543.
52. Zauli G., Melloni E., Capitani S., Secchiero P. Role of full-length osteoprotegerin in tumor cell biology. Cell. Mol. Life Sci. 2009, 66:841-851.
53. Zauli G., Toffoli B., di Iasio M.G., Celeghini C., Fabris B., Secchiero P. Treatment with recombinant tumor necrosis factor-related apoptosis-inducing ligand alleviates the severity of streptozotocin-induced diabetes. Diabetes 2010, 59:1261-1265.
54. Zhang J., Fu M., Myles D., Zhu X., Du J., Cao X., Chen Y.E. PDGF induces osteoprotegerin expression in vascular smooth muscle cells by multiple signal pathways. FEBS Lett. 2002, 521:180-184.